Overview
SCIENTIFIC SCORE
Possibly Effective
Based on 14 Researches
7.6
USERS' SCORE
Good
Based on 3 Reviews
8.3
Supplement Facts
Serving Size: 1 Veggie Capsule
Serving Per Container: 60
Amount Per Serving
%DV
Coenzyme Q10 (Ubiquinone)
200 mg
†
Black Pepper Ext. (Piper nigrum) (fruit) (standardized to contain 95% Piperine) (BioPerine®)
5 mg
†
Top Medical Research Studies
9.5
We explored the potential benefits of idebenone, a synthetic analog of coenzyme Q10, in treating autoimmune disorders, specifically lupus, in mouse models. By administering idebenone to mice with lupus for eight weeks, we aimed to investigate its impact on disease activity and organ damage.
Our findings showed that idebenone led to a significant reduction in disease severity. Mice that received idebenone exhibited lower mortality rates and improvements in kidney function, indicated by reduced glomerular inflammation and lower levels of certain inflammatory markers. The treatment also minimized the production of proinflammatory cytokines and enhanced mitochondrial metabolism.
Besides benefiting the kidneys, idebenone diminished markers of inflammation throughout the body, which is crucial since lupus often results in systemic damage. Importantly, we noticed that idebenone improved overall metabolism in these mice without causing obvious side effects.
This research supports the idea that modulating mitochondrial function can be a promising therapeutic strategy for managing lupus, opening the door for future studies on its effectiveness in humans.
Our findings showed that idebenone led to a significant reduction in disease severity. Mice that received idebenone exhibited lower mortality rates and improvements in kidney function, indicated by reduced glomerular inflammation and lower levels of certain inflammatory markers. The treatment also minimized the production of proinflammatory cytokines and enhanced mitochondrial metabolism.
Besides benefiting the kidneys, idebenone diminished markers of inflammation throughout the body, which is crucial since lupus often results in systemic damage. Importantly, we noticed that idebenone improved overall metabolism in these mice without causing obvious side effects.
This research supports the idea that modulating mitochondrial function can be a promising therapeutic strategy for managing lupus, opening the door for future studies on its effectiveness in humans.
Read More
9
CoQ10 shows promise for autoimmune treatment
We explored the effects of coenzyme Q10 (CoQ10) as a treatment for various autoimmune disorders. Over a period from 1966 to April 2023, we reviewed 20 articles encompassing a total of 483 patients, focusing on conditions such as Fibromyalgia (FM), Rheumatoid Arthritis (RA), and Antiphospholipid Syndrome (APS).
Our findings revealed that CoQ10 supplementation resulted in notable improvements, especially for patients with RA. Specifically, these patients showed enhancements in disease activity index and reductions in inflammatory markers, including erythrocyte sedimentation rate and malondialdehyde levels. For those with APS, CoQ10 exhibited benefits such as improved endothelial function and reduced pro-inflammatory markers.
When it came to FM, most studies indicated that individuals experienced relief in symptoms related to pain, fatigue, sleep disturbances, and mood disorders. Notably, the treatment was well-received, with only minor side effects reported in a couple of cases.
Overall, CoQ10 appears to be an effective complementary treatment option for patients suffering from RA and FM. However, we encourage further research involving larger sample sizes and additional autoimmune conditions to better understand its efficacy.
Our findings revealed that CoQ10 supplementation resulted in notable improvements, especially for patients with RA. Specifically, these patients showed enhancements in disease activity index and reductions in inflammatory markers, including erythrocyte sedimentation rate and malondialdehyde levels. For those with APS, CoQ10 exhibited benefits such as improved endothelial function and reduced pro-inflammatory markers.
When it came to FM, most studies indicated that individuals experienced relief in symptoms related to pain, fatigue, sleep disturbances, and mood disorders. Notably, the treatment was well-received, with only minor side effects reported in a couple of cases.
Overall, CoQ10 appears to be an effective complementary treatment option for patients suffering from RA and FM. However, we encourage further research involving larger sample sizes and additional autoimmune conditions to better understand its efficacy.
Read More
9
CoQ10 improves rheumatoid arthritis symptoms
We conducted a randomized, double-blind, placebo-controlled trial to investigate the potential benefits of coenzyme Q10 (CoQ10) supplementation for individuals with rheumatoid arthritis (RA). Our group included 54 participants who were assigned to receive either 100 mg of CoQ10 or a placebo daily for two months. We carefully measured changes in serum matrix metalloproteinases (MMPs), as well as clinical parameters like the Disease Activity Score in 28 joints (DAS-28) before and after the treatment period.
The results were quite promising. We observed that CoQ10 significantly reduced the level of MMP-3 and improved various clinical outcomes—showing a notable drop in DAS-28 scores which indicates reduced disease activity. Furthermore, patients taking CoQ10 experienced significant reductions in swollen and tender joint counts, pain scores, and erythrocyte sedimentation rate (ESR) compared to their initial readings.
Overall, the findings suggest that CoQ10 supplementation may complement standard treatments for rheumatoid arthritis, helping to reduce inflammation and improve joint health. This new approach could offer hope for RA patients looking for additional management options.
The results were quite promising. We observed that CoQ10 significantly reduced the level of MMP-3 and improved various clinical outcomes—showing a notable drop in DAS-28 scores which indicates reduced disease activity. Furthermore, patients taking CoQ10 experienced significant reductions in swollen and tender joint counts, pain scores, and erythrocyte sedimentation rate (ESR) compared to their initial readings.
Overall, the findings suggest that CoQ10 supplementation may complement standard treatments for rheumatoid arthritis, helping to reduce inflammation and improve joint health. This new approach could offer hope for RA patients looking for additional management options.
Read More
Most Useful Reviews
9
Tremors reduced
2 people found this helpful
I've taken CoQ10 for over 10 years as I have a relative with Parkinson's disease. I noticed my hand tremors haven't worsened, and my hearing loss has barely progressed. After a few months without it, my tremors increased, so I reordered. Within two weeks of taking CoQ10 again, they improved significantly. I believe it is effective for my autoimmune disorder.
Read More
7.5
Improved energy
After taking this for two months, my condition has improved significantly. I have more energy, less fatigue, and my emotional state has enhanced—particularly as I returned to work after three years of maternity leave. I recommend it and will order more to help with my autoimmune disorder.
Read More
7
Supports heart health
4 people found this helpful
I have been ordering these for many years for my mother, who has a sick heart. For the past four years, she has been taking them, and it seems they support her heart and help her appear younger. I will continue to buy them for her.
Read More
Medical Researches
SCIENTIFIC SCORE
Possibly Effective
Based on 14 Researches
7.6
- All Researches
9.5
We explored the potential benefits of idebenone, a synthetic analog of coenzyme Q10, in treating autoimmune disorders, specifically lupus, in mouse models. By administering idebenone to mice with lupus for eight weeks, we aimed to investigate its impact on disease activity and organ damage.
Our findings showed that idebenone led to a significant reduction in disease severity. Mice that received idebenone exhibited lower mortality rates and improvements in kidney function, indicated by reduced glomerular inflammation and lower levels of certain inflammatory markers. The treatment also minimized the production of proinflammatory cytokines and enhanced mitochondrial metabolism.
Besides benefiting the kidneys, idebenone diminished markers of inflammation throughout the body, which is crucial since lupus often results in systemic damage. Importantly, we noticed that idebenone improved overall metabolism in these mice without causing obvious side effects.
This research supports the idea that modulating mitochondrial function can be a promising therapeutic strategy for managing lupus, opening the door for future studies on its effectiveness in humans.
Our findings showed that idebenone led to a significant reduction in disease severity. Mice that received idebenone exhibited lower mortality rates and improvements in kidney function, indicated by reduced glomerular inflammation and lower levels of certain inflammatory markers. The treatment also minimized the production of proinflammatory cytokines and enhanced mitochondrial metabolism.
Besides benefiting the kidneys, idebenone diminished markers of inflammation throughout the body, which is crucial since lupus often results in systemic damage. Importantly, we noticed that idebenone improved overall metabolism in these mice without causing obvious side effects.
This research supports the idea that modulating mitochondrial function can be a promising therapeutic strategy for managing lupus, opening the door for future studies on its effectiveness in humans.
Read More
9
CoQ10 shows promise for autoimmune treatment
We explored the effects of coenzyme Q10 (CoQ10) as a treatment for various autoimmune disorders. Over a period from 1966 to April 2023, we reviewed 20 articles encompassing a total of 483 patients, focusing on conditions such as Fibromyalgia (FM), Rheumatoid Arthritis (RA), and Antiphospholipid Syndrome (APS).
Our findings revealed that CoQ10 supplementation resulted in notable improvements, especially for patients with RA. Specifically, these patients showed enhancements in disease activity index and reductions in inflammatory markers, including erythrocyte sedimentation rate and malondialdehyde levels. For those with APS, CoQ10 exhibited benefits such as improved endothelial function and reduced pro-inflammatory markers.
When it came to FM, most studies indicated that individuals experienced relief in symptoms related to pain, fatigue, sleep disturbances, and mood disorders. Notably, the treatment was well-received, with only minor side effects reported in a couple of cases.
Overall, CoQ10 appears to be an effective complementary treatment option for patients suffering from RA and FM. However, we encourage further research involving larger sample sizes and additional autoimmune conditions to better understand its efficacy.
Our findings revealed that CoQ10 supplementation resulted in notable improvements, especially for patients with RA. Specifically, these patients showed enhancements in disease activity index and reductions in inflammatory markers, including erythrocyte sedimentation rate and malondialdehyde levels. For those with APS, CoQ10 exhibited benefits such as improved endothelial function and reduced pro-inflammatory markers.
When it came to FM, most studies indicated that individuals experienced relief in symptoms related to pain, fatigue, sleep disturbances, and mood disorders. Notably, the treatment was well-received, with only minor side effects reported in a couple of cases.
Overall, CoQ10 appears to be an effective complementary treatment option for patients suffering from RA and FM. However, we encourage further research involving larger sample sizes and additional autoimmune conditions to better understand its efficacy.
Read More
9
In a comprehensive study, we explored the potential benefits of Coenzyme Q10 (CoQ10) in addressing the challenges of Multiple Sclerosis (MS), a chronic autoimmune disorder that leads to the degradation of protective myelin in the central nervous system. Using a well-established mouse model, we divided the animals into groups—some receiving a diet containing cuprizone (CPZ) to induce MS symptoms, while one group was also given CoQ10 to assess its impact on demyelination and remyelination.
Over a period of 12 weeks, the effects of CoQ10 were assessed through behavioral tests and molecular analyses. We noted improvements in the histological results for those treated with CoQ10, including increased levels of myelin basic protein and specific markers that indicate support for oligodendrocyte health. These findings suggest that CoQ10 administration can significantly promote remyelination and reduce oxidative stress and inflammation linked to CPZ exposure.
While the CPZ group did not exhibit significant differences in behavioral tests compared to controls, the positive cellular and histological outcomes demonstrated the treatment's promise. Overall, our findings could imply that CoQ10 might be beneficial in managing remyelination processes in MS, although further research in human subjects is needed to fully understand its potential.
Over a period of 12 weeks, the effects of CoQ10 were assessed through behavioral tests and molecular analyses. We noted improvements in the histological results for those treated with CoQ10, including increased levels of myelin basic protein and specific markers that indicate support for oligodendrocyte health. These findings suggest that CoQ10 administration can significantly promote remyelination and reduce oxidative stress and inflammation linked to CPZ exposure.
While the CPZ group did not exhibit significant differences in behavioral tests compared to controls, the positive cellular and histological outcomes demonstrated the treatment's promise. Overall, our findings could imply that CoQ10 might be beneficial in managing remyelination processes in MS, although further research in human subjects is needed to fully understand its potential.
Read More
9
We explored the anti-inflammatory effects of Coenzyme Q10 (CoQ10) using liposome/gold hybrid nanoparticles, referred to as LGNP-CoQ10, specifically in the context of rheumatoid arthritis. The study involved administering both CoQ10 and LGNP-CoQ10 orally to mice suffering from collagen-induced arthritis (CIA) over a period of 10 weeks.
To understand the impact, we analyzed the joint tissues for inflammation pathology and also looked closely at the immune response through various staining techniques. Our findings revealed a notable decrease in pro-inflammatory cytokines and populations of Th17 cells, which are commonly associated with autoimmune responses, in the mice treated with LGNP-CoQ10.
Additionally, when we tested human peripheral blood mononuclear cells, we observed that the IL-17 expression significantly dropped when treated with the LGNP-CoQ10 formulation. This suggests that the hybrid nanoparticle approach effectively enhances the anti-inflammatory properties of CoQ10, indicating its potential as a therapeutic option for rheumatoid arthritis.
To understand the impact, we analyzed the joint tissues for inflammation pathology and also looked closely at the immune response through various staining techniques. Our findings revealed a notable decrease in pro-inflammatory cytokines and populations of Th17 cells, which are commonly associated with autoimmune responses, in the mice treated with LGNP-CoQ10.
Additionally, when we tested human peripheral blood mononuclear cells, we observed that the IL-17 expression significantly dropped when treated with the LGNP-CoQ10 formulation. This suggests that the hybrid nanoparticle approach effectively enhances the anti-inflammatory properties of CoQ10, indicating its potential as a therapeutic option for rheumatoid arthritis.
Read More
9
CoQ10 improves rheumatoid arthritis symptoms
We conducted a randomized, double-blind, placebo-controlled trial to investigate the potential benefits of coenzyme Q10 (CoQ10) supplementation for individuals with rheumatoid arthritis (RA). Our group included 54 participants who were assigned to receive either 100 mg of CoQ10 or a placebo daily for two months. We carefully measured changes in serum matrix metalloproteinases (MMPs), as well as clinical parameters like the Disease Activity Score in 28 joints (DAS-28) before and after the treatment period.
The results were quite promising. We observed that CoQ10 significantly reduced the level of MMP-3 and improved various clinical outcomes—showing a notable drop in DAS-28 scores which indicates reduced disease activity. Furthermore, patients taking CoQ10 experienced significant reductions in swollen and tender joint counts, pain scores, and erythrocyte sedimentation rate (ESR) compared to their initial readings.
Overall, the findings suggest that CoQ10 supplementation may complement standard treatments for rheumatoid arthritis, helping to reduce inflammation and improve joint health. This new approach could offer hope for RA patients looking for additional management options.
The results were quite promising. We observed that CoQ10 significantly reduced the level of MMP-3 and improved various clinical outcomes—showing a notable drop in DAS-28 scores which indicates reduced disease activity. Furthermore, patients taking CoQ10 experienced significant reductions in swollen and tender joint counts, pain scores, and erythrocyte sedimentation rate (ESR) compared to their initial readings.
Overall, the findings suggest that CoQ10 supplementation may complement standard treatments for rheumatoid arthritis, helping to reduce inflammation and improve joint health. This new approach could offer hope for RA patients looking for additional management options.
Read More
User Reviews
USERS' SCORE
Good
Based on 3 Reviews
8.3
- All Reviews
- Positive Reviews
- Negative Reviews
9
Tremors reduced
2 people found this helpful
I've taken CoQ10 for over 10 years as I have a relative with Parkinson's disease. I noticed my hand tremors haven't worsened, and my hearing loss has barely progressed. After a few months without it, my tremors increased, so I reordered. Within two weeks of taking CoQ10 again, they improved significantly. I believe it is effective for my autoimmune disorder.
Read More
7.5
Improved energy
After taking this for two months, my condition has improved significantly. I have more energy, less fatigue, and my emotional state has enhanced—particularly as I returned to work after three years of maternity leave. I recommend it and will order more to help with my autoimmune disorder.
Read More
7
Supports heart health
4 people found this helpful
I have been ordering these for many years for my mother, who has a sick heart. For the past four years, she has been taking them, and it seems they support her heart and help her appear younger. I will continue to buy them for her.
Read More
Frequently Asked Questions
9
Tremors reduced
2 people found this helpful
I've taken CoQ10 for over 10 years as I have a relative with Parkinson's disease. I noticed my hand tremors haven't worsened, and my hearing loss has barely progressed. After a few months without it, my tremors increased, so I reordered. Within two weeks of taking CoQ10 again, they improved significantly. I believe it is effective for my autoimmune disorder.
7.5
Improved energy
After taking this for two months, my condition has improved significantly. I have more energy, less fatigue, and my emotional state has enhanced—particularly as I returned to work after three years of maternity leave. I recommend it and will order more to help with my autoimmune disorder.
7
Supports heart health
4 people found this helpful
I have been ordering these for many years for my mother, who has a sick heart. For the past four years, she has been taking them, and it seems they support her heart and help her appear younger. I will continue to buy them for her.
9
CoQ10 shows promise for autoimmune treatment
We explored the effects of coenzyme Q10 (CoQ10) as a treatment for various autoimmune disorders. Over a period from 1966 to April 2023, we reviewed 20 articles encompassing a total of 483 patients, focusing on conditions such as Fibromyalgia (FM), Rheumatoid Arthritis (RA), and Antiphospholipid Syndrome (APS).
Our findings revealed that CoQ10 supplementation resulted in notable improvements, especially for patients with RA. Specifically, these patients showed enhancements in disease activity index and reductions in inflammatory markers, including erythrocyte sedimentation rate and malondialdehyde levels. For those with APS, CoQ10 exhibited benefits such as improved endothelial function and reduced pro-inflammatory markers.
When it came to FM, most studies indicated that individuals experienced relief in symptoms related to pain, fatigue, sleep disturbances, and mood disorders. Notably, the treatment was well-received, with only minor side effects reported in a couple of cases.
Overall, CoQ10 appears to be an effective complementary treatment option for patients suffering from RA and FM. However, we encourage further research involving larger sample sizes and additional autoimmune conditions to better understand its efficacy.
Our findings revealed that CoQ10 supplementation resulted in notable improvements, especially for patients with RA. Specifically, these patients showed enhancements in disease activity index and reductions in inflammatory markers, including erythrocyte sedimentation rate and malondialdehyde levels. For those with APS, CoQ10 exhibited benefits such as improved endothelial function and reduced pro-inflammatory markers.
When it came to FM, most studies indicated that individuals experienced relief in symptoms related to pain, fatigue, sleep disturbances, and mood disorders. Notably, the treatment was well-received, with only minor side effects reported in a couple of cases.
Overall, CoQ10 appears to be an effective complementary treatment option for patients suffering from RA and FM. However, we encourage further research involving larger sample sizes and additional autoimmune conditions to better understand its efficacy.
7
We explored the impact of Coenzyme Q10 (CoQ10) supplementation on multiple sclerosis (MS), an autoimmune disorder that significantly affects the central nervous system. Our approach followed established systematic review methods, analyzing studies that looked into how CoQ10 might influence oxidative stress, inflammation, and clinical symptoms in MS patients.
Through our review of existing research, we observed that CoQ10 appears to have beneficial, dose-dependent effects, helping to reduce oxidative stress and inflammation in individuals with MS. Moreover, there are indications that it could provide relief from some clinical symptoms linked to the disease. However, we must recognize the limitations of the evidence, notably the small number of studies included in our review.
It's also important to note that definitive clinical recommendations cannot yet be made, as future studies are necessary to build a more substantial body of evidence. Thus, while CoQ10 shows promise, more research is needed to fully understand its role in managing autoimmune disorders like MS.
Through our review of existing research, we observed that CoQ10 appears to have beneficial, dose-dependent effects, helping to reduce oxidative stress and inflammation in individuals with MS. Moreover, there are indications that it could provide relief from some clinical symptoms linked to the disease. However, we must recognize the limitations of the evidence, notably the small number of studies included in our review.
It's also important to note that definitive clinical recommendations cannot yet be made, as future studies are necessary to build a more substantial body of evidence. Thus, while CoQ10 shows promise, more research is needed to fully understand its role in managing autoimmune disorders like MS.
7
We examined a unique case of a 7-year-old boy diagnosed with IgA nephropathy who also showed signs of a specific genetic condition related to the COQ8B gene. Despite treatment with steroid medications, cyclophosphamide, and other therapies, the child's kidney function continued to decline.
In this context, we observed the use of high-dose coenzyme Q10 in conjunction with these treatments. While coenzyme Q10 has been proposed as a potential aid, after 7.3 years of treatment, the child’s condition did not significantly improve, as indicated by rising serum creatinine levels.
This finding suggests that coenzyme Q10 may not have the expected benefit in addressing the autoimmune aspects of his kidney disorder when used alongside other treatments. The study highlights the importance of considering additional underlying diseases in children with complex presentations of kidney disorders.
In this context, we observed the use of high-dose coenzyme Q10 in conjunction with these treatments. While coenzyme Q10 has been proposed as a potential aid, after 7.3 years of treatment, the child’s condition did not significantly improve, as indicated by rising serum creatinine levels.
This finding suggests that coenzyme Q10 may not have the expected benefit in addressing the autoimmune aspects of his kidney disorder when used alongside other treatments. The study highlights the importance of considering additional underlying diseases in children with complex presentations of kidney disorders.
7
Coenzyme Q10's potential in treatment
Our systematic review examined how coenzyme Q10 might influence autoimmune disorders, an area of growing interest given the challenges faced by individuals living with these conditions. We analyzed data from multiple randomized controlled trials to determine if this nutraceutical could offer any improvements in clinical outcomes for patients.
The findings revealed that coenzyme Q10 has been tested in a few studies for its effects on biological and clinical measures related to autoimmune disorders. While some improvements were noted, particularly in aspects like fatigue and overall well-being, it’s essential to highlight that the studies were relatively small. Thus, conclusions drawn from these trials must be approached with caution.
Moreover, the research indicates a need for larger-scale studies to confirm these initial findings. It's clear that while there is some promise in the potential benefits of coenzyme Q10 for those with autoimmune disorders, more robust evidence is required to firmly establish its role in treatment regimens.
The findings revealed that coenzyme Q10 has been tested in a few studies for its effects on biological and clinical measures related to autoimmune disorders. While some improvements were noted, particularly in aspects like fatigue and overall well-being, it’s essential to highlight that the studies were relatively small. Thus, conclusions drawn from these trials must be approached with caution.
Moreover, the research indicates a need for larger-scale studies to confirm these initial findings. It's clear that while there is some promise in the potential benefits of coenzyme Q10 for those with autoimmune disorders, more robust evidence is required to firmly establish its role in treatment regimens.
9
CoQ10 improves rheumatoid arthritis symptoms
We conducted a randomized, double-blind, placebo-controlled trial to investigate the potential benefits of coenzyme Q10 (CoQ10) supplementation for individuals with rheumatoid arthritis (RA). Our group included 54 participants who were assigned to receive either 100 mg of CoQ10 or a placebo daily for two months. We carefully measured changes in serum matrix metalloproteinases (MMPs), as well as clinical parameters like the Disease Activity Score in 28 joints (DAS-28) before and after the treatment period.
The results were quite promising. We observed that CoQ10 significantly reduced the level of MMP-3 and improved various clinical outcomes—showing a notable drop in DAS-28 scores which indicates reduced disease activity. Furthermore, patients taking CoQ10 experienced significant reductions in swollen and tender joint counts, pain scores, and erythrocyte sedimentation rate (ESR) compared to their initial readings.
Overall, the findings suggest that CoQ10 supplementation may complement standard treatments for rheumatoid arthritis, helping to reduce inflammation and improve joint health. This new approach could offer hope for RA patients looking for additional management options.
The results were quite promising. We observed that CoQ10 significantly reduced the level of MMP-3 and improved various clinical outcomes—showing a notable drop in DAS-28 scores which indicates reduced disease activity. Furthermore, patients taking CoQ10 experienced significant reductions in swollen and tender joint counts, pain scores, and erythrocyte sedimentation rate (ESR) compared to their initial readings.
Overall, the findings suggest that CoQ10 supplementation may complement standard treatments for rheumatoid arthritis, helping to reduce inflammation and improve joint health. This new approach could offer hope for RA patients looking for additional management options.
8
We explored the impact of coenzyme Q10 (CoQ10) on autoimmune disorders, specifically in the context of systemic lupus erythematosus (SLE). This compound has gained attention due to its potential to restore energy balance within cells and reduce oxidative stress.
The relationship between CoQ10 and autoimmune disorders centers around its ability to improve mitochondrial function. In SLE patients, mitochondrial dysfunction is a significant factor contributing to disease progression, leading to inflammation and immune dysregulation. Our investigation brought to light promising results from various studies where CoQ10 showed potential in reducing disease activity and improving overall well-being in affected individuals.
As we sift through the available data, we find that CoQ10 can indeed serve as a beneficial adjunctive treatment. Its antioxidant properties appear to alleviate some of the biochemical disturbances observed in autoimmune diseases, opening the door for its use in broader therapeutic strategies. However, more comprehensive research is needed to fully understand the extent of its effects and how best to incorporate it into treatment plans.
The relationship between CoQ10 and autoimmune disorders centers around its ability to improve mitochondrial function. In SLE patients, mitochondrial dysfunction is a significant factor contributing to disease progression, leading to inflammation and immune dysregulation. Our investigation brought to light promising results from various studies where CoQ10 showed potential in reducing disease activity and improving overall well-being in affected individuals.
As we sift through the available data, we find that CoQ10 can indeed serve as a beneficial adjunctive treatment. Its antioxidant properties appear to alleviate some of the biochemical disturbances observed in autoimmune diseases, opening the door for its use in broader therapeutic strategies. However, more comprehensive research is needed to fully understand the extent of its effects and how best to incorporate it into treatment plans.
References
- Salekzamani S, Pakkhesal S, Babaei M, Mirzaaghazadeh E, Mosaddeghi-Heris R, et al. Coenzyme Q10 supplementation in multiple sclerosis; A systematic review. Mult Scler Relat Disord. 2025;93:106212. doi:10.1016/j.msard.2024.106212
- Sun L, Xiao H, Ren Y, Xu K, Zhong X, et al. [Clinical and genetic analysis of a child with co-morbid progressive IgA nephropathy and COQ8B-associated glomerulopathy]. Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2024;41:1231. doi:10.3760/cma.j.cn511374-20240305-00144
- Poznyak AV, Orekhov NA, Churov AV, Starodubtseva IA, Beloyartsev DF, et al. Mitochondrial Dysfunction in Systemic Lupus Erythematosus: Insights and Therapeutic Potential. Diseases. 2024;12. doi:10.3390/diseases12090226
- Freire de Carvalho J, Skare T. Coenzyme Q10 supplementation in rheumatic diseases: A systematic review. Clin Nutr ESPEN. 2024;59:63. doi:10.1016/j.clnesp.2023.11.016
- Hossein Haghighi A, Ahmadi A, Carotenuto A, Askari R, Nikkhah K, et al. Effects of concurrent training and CoQ10 on neurotrophic factors and physical function in people with Multiple Sclerosis: a pilot study. Eur J Transl Myol. 2023;33. doi:10.4081/ejtm.2023.11253
- Abdelkader HA, Rashed LA, Assaad E, Saleh MA. Serum and tissue levels of coenzyme Q10 in pemphigus vulgaris. J Cosmet Dermatol. 2022;21:3002. doi:10.1111/jocd.14511
- Kucharská J, Poništ S, Vančová O, Gvozdjáková A, Uličná O, et al. Treatment with coenzyme Q10, omega-3-polyunsaturated fatty acids and their combination improved bioenergetics and levels of coenzyme Q9 and Q10 in skeletal muscle mitochondria in experimental model of arthritis. Physiol Res. 2021;70:723.
- López-Pedrera C, Villalba JM, Patiño-Trives AM, Luque-Tévar M, Barbarroja N, et al. Therapeutic Potential and Immunomodulatory Role of Coenzyme Q and Its Analogues in Systemic Autoimmune Diseases. Antioxidants (Basel). 2021;10. doi:10.3390/antiox10040600
- Kour G, Haq SA, Bajaj BK, Gupta PN, Ahmed Z. Phytochemical add-on therapy to DMARDs therapy in rheumatoid arthritis: In vitro and in vivo bases, clinical evidence and future trends. Pharmacol Res. 2021;169:105618. doi:10.1016/j.phrs.2021.105618
- Khalilian B, Madadi S, Fattahi N, Abouhamzeh B. Coenzyme Q10 enhances remyelination and regulate inflammation effects of cuprizone in corpus callosum of chronic model of multiple sclerosis. J Mol Histol. 2021;52:125. doi:10.1007/s10735-020-09929-x
- Jhun J, Moon J, Ryu J, Shin Y, Lee S, et al. Liposome/gold hybrid nanoparticle encoded with CoQ10 (LGNP-CoQ10) suppressed rheumatoid arthritis via STAT3/Th17 targeting. PLoS One. 2020;15:e0241080. doi:10.1371/journal.pone.0241080
- Marx W, Hockey M, McGuinness AJ, Lane M, Christodoulou J, et al. The effect of emerging nutraceutical interventions for clinical and biological outcomes in multiple sclerosis: A systematic review. Mult Scler Relat Disord. 2020;37:101486. doi:10.1016/j.msard.2019.101486
- Blanco LP, Pedersen HL, Wang X, Lightfoot YL, Seto N, et al. Improved Mitochondrial Metabolism and Reduced Inflammation Following Attenuation of Murine Lupus With Coenzyme Q10 Analog Idebenone. Arthritis Rheumatol. 2020;72:454. doi:10.1002/art.41128
- Nachvak SM, Alipour B, Mahdavi AM, Aghdashi MA, Abdollahzad H, et al. Effects of coenzyme Q10 supplementation on matrix metalloproteinases and DAS-28 in patients with rheumatoid arthritis: a randomized, double-blind, placebo-controlled clinical trial. Clin Rheumatol. 2019;38:3367. doi:10.1007/s10067-019-04723-x
